Topics we study

The science of extending healthy lifespan — the biology of aging, the interventions claimed to slow it, and the evidence that separates the two.

Insulin, glucose, body composition, and the incretin revolution — the metabolic systems at the center of modern longevity medicine.

Semaglutide, tirzepatide, retatrutide, and the incretin pipeline — the pharmacology, the market, and the claims made about their effects beyond weight.

From approved medicines to research-use-only compounds — the science, the subculture, and the evidence gaps across the peptide universe.

Pricing, seller structure, and demand across the research-use-only peptide economy — where the market prices attention rather than evidence.

The cellular and molecular hallmarks of aging — and how honestly they map onto the interventions marketed against them.

Diet, muscle, and fat — the levers of body composition and the evidence behind the protocols that promise to move them.

Cognition, recovery, and physical capacity — the technologies and compounds aimed at optimizing how the body and brain perform.